BiotechTube

Cetuximab + Cisplatin

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Conditions

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Trial Timeline

Jan 14, 2020 → May 23, 2023

NCT ID
NCT04106362

About Cetuximab + Cisplatin

Cetuximab + Cisplatin is a phase 2 stage product being developed by Eli Lilly for Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8. The current trial status is terminated. This product is registered under clinical trial identifier NCT04106362. Target conditions include Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant.

What happened to similar drugs?

1 of 4 similar drugs in Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 were approved

Approved (1) Terminated (1) Active (3)
🔄Lecanemab + PlaceboEisaiPhase 3
✅PosaconazoleMerckApproved
🔄Rebif®MerckPhase 3
🔄Cannabidiol (CBD) + PlaceboJazz PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04106362Phase 2Terminated

Competing Products

20 competing products in Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

See all competitors
ProductCompanyStageHype Score
Lecanemab + PlaceboEisaiPhase 3
44
Durvalumab + TremelimumabAstraZenecaPhase 1/2
24
PosaconazoleMerckApproved
35
Rebif®MerckPhase 3
40
Blinatumomab + olverembatinibAmgenPhase 2
42
Binimetinib + NivolumabBristol Myers SquibbPhase 2
27
Fluconazole (BAYT006267) 150 mg capsules + Fluconazole 150 mg capsules (DiflucanTM)BayerPhase 1
26
Finerenone (BAY 94-8862) PEG solution + Finerenone (BAY 94-8862) immediate release tablet + Eplerenone (Inspra®) + PlaceboBayerPhase 1
26
Rivaroxaban (BAY 59-7939, Xarelto) in ODT form + Rivaroxaban (BAY 59-7939, Xarelto) in film-coated formBayerPhase 1
26
Naproxen sodium and diphenhydramine hydrochloride soft capsules + Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)BayerPhase 1
26
Fulacimstat (BAY1142524)BayerPhase 1
26
Vilaprisan (BAY 1002670) + Vilaprisan Placebo + Microgynon + Microgynon PlaceboBayerPhase 1
26
Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetilBayerPhase 1
26
BAY1817080 + Placebo + ItraconazoleBayerPhase 1
26
BAY1902607 + PlaceboBayerPhase 1
26
Fosrenol ODT (Lanthanum Carbonate, BAY77-1931) + Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)BayerPhase 1
26
Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg + PlaceboBayerPhase 1
26
Neladenoson bialanate (BAY 1067197)BayerPhase 1
18
Riociguat (Adempas, BAY 63-2521)BayerPhase 1
26
Vilaprisan (BAY1002670)BayerPhase 1
26